• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Tourmaline Bio Inc.

    4/21/25 4:09:39 PM ET
    $TRML
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TRML alert in real time by email
    DEFA14A 1 a04212025defa14a.htm DEFA14A Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
     
    SCHEDULE 14A
    Proxy Statement Pursuant to Section 14(a) of the
    Securities Exchange Act of 1934
    (Amendment No. )

     

    Filed by the Registrant ☒
    Filed by a Party other than the Registrant ☐

    Check the appropriate box:
    ☐    Preliminary Proxy Statement
    ☐    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ☐    Definitive Proxy Statement
    ☒    Definitive Additional Materials
    ☐    Soliciting Material Pursuant to §240.14a-12
    Tourmaline Bio, Inc.
    (Name of Registrant as Specified In Its Charter)

    N/A
    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)
    Payment of Filing Fee (Check the appropriate box):
    ☒    No fee required.
    ☐    Fee paid previously with preliminary materials.
    ☐    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11






    trml2025noticepage1.jpg



    trml2025noticepage2.jpg




    Get the next $TRML alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TRML

    DatePrice TargetRatingAnalyst
    4/23/2025$70.00Buy
    Chardan Capital Markets
    3/6/2025$42.00Outperform
    Wedbush
    12/6/2024$50.00Outperform
    BMO Capital Markets
    11/11/2024$48.00 → $49.00Buy
    H.C. Wainwright
    12/15/2023$41.00Buy
    Jefferies
    12/4/2023$48.00Buy
    H.C. Wainwright
    11/17/2023$43.00Buy
    Truist
    10/31/2023$50.00Buy
    Guggenheim
    More analyst ratings

    $TRML
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO Kulkarni Sandeep Chidambar bought $26,418 worth of shares (1,779 units at $14.85) (SEC Form 4)

      4 - Tourmaline Bio, Inc. (0001827506) (Issuer)

      8/22/24 4:22:14 PM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CEO Kulkarni Sandeep Chidambar bought $71,998 worth of shares (5,221 units at $13.79) (SEC Form 4)

      4 - Tourmaline Bio, Inc. (0001827506) (Issuer)

      8/20/24 6:09:47 PM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care